HUNTINGTON, N.Y. - September 9, 2022 - (Newswire.com)
Cold Spring Plastic Surgery, a Long Island plastic surgery center that offers a full range of cosmetic and reconstructive procedures, recently announced that they will offer a discount on Qwo cellulite treatment for $500 less than the normal price.
Qwo is the first injectable cellulite treatment to have been approved by the FDA. Designed to address what's considered "moderate to severe" buttocks cellulite, Qwo is made of enzymes that break down and ultimately release fibrous septae (the cause of cellulite's appearance).
Cold Spring Plastic Surgery delivers Qwo in three injection treatments. Each injection at Cold Spring takes roughly ten minutes on average. During each of those treatments, Cold Spring plastic surgeons target the fibrous septae so that the patient's fat cells can be redistributed as new collagen is being produced. The goal of this treatment is to leave every patient with an appearance that is smoother and more toned.
"It's hard to feel as confident about yourself as you should be when you're dealing with cellulite. Yes, it's a naturally occurring phenomenon, but it can negatively affect your self-image and sense of comfort, all leading to you feeling less confident. Even if you eat right, exercise, and take care of yourself, that doesn't mean that you'll be able to get rid of cellulite. That's where our Qwo comes in. Here, our experienced, pro plastic surgeons can treat you right, providing you with care that gives you maximum results for minimum downtime. Indeed, you'll be back to regular activities the day after getting your Qwo treatment. With summer upon us, we know how folks want to look their best when they're at the beach, out and about, and so forth. That's why we're currently offering a discount on Qwo. We see it as one more way to help people to look and feel better," said Joseph Batac of Cold Spring Plastic Surgery.
In addition to Qwo, Cold Spring Plastic Surgery also offers cosmetic surgery services, hand surgery services, chemical peels, Botox, and reconstructive surgery among many, many other services. Those interested should request a consultation through their site or by calling (631) 470-9650 or (212) 472-2022.
For more information about cellulite treatment, Qwo, or to make a press inquiry, you can reach Cold Spring Plastic Surgery at https://www.coldspringplasticsurgery.com/
As published in Frontiers in Pharmacology, the biopharmaceutical drug development firm's sponsored research has identified and validated cannabinoid ratio-controlled, Minimum Essential Mixtures (MEM) for the treatment of Parkinson's disease symptoms
Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, has co-published a study in the journal Frontiers in Pharmacologythat demonstrates the efficacy of its proprietary cannabinoid-containing, minimum essential mixtures (MEM) for the treatment of Parkinson's disease (PD). There is a great clinical need for improved therapeutics, and the market for Parkinson's disease treatments is expected to grow to $8.8 billion by 2026.
"Our drug discovery process has identified promising ratio-controlled mixtures of cannabis-inspired compounds for the treatment of Parkinson's disease, which have proven effective at reducing Parkinsonian motor symptoms in an animal model of the disease," said Dr. Andrea Small Howard, President, Chief Science Officer, and Director of Gb Sciences. "This study allows us to continue addressing unmet clinical needs through the development of novel plant-inspired drugs, and positions Gb Sciences as a contributor to the expanding world of novel PD therapeutics."
For this Gb Sciences-sponsored study, the discovery research using cell models of Parkinson's disease was performed at Chaminade University (Honolulu, Hawai'i, USA), and the MEM refinement and validation research was performed in a zebrafish model of Parkinson's disease at the National Research Council of Canada (NRC). The study entitled "Identification of minimum essential therapeutic mixtures from Cannabis plant extracts by screening in cell and animal models of Parkinson's disease" was co-authored by Gb Sciences' own President and Chief Science Officer Andrea Small-Howard and her collaborators Michael G. Morash, Jessica Nixon, and Lee Ellis from the National Research Council of Canada; Lori M.N. Shimoda and Helen Turner from Chaminade University of Honolulu; and Alexander J. Stokes from the University of Hawai'i at Manoa (Manoa, Hawai'i, USA).
The sequentially reductionist process implemented in this multi-site study preserves some of the entourage-like effects of whole plant extracts while achieving "relative" simplicity within MEM that is a requirement for obtaining the manufacturing and quality control advantages of single-ingredient drugs. This paper identifies promising minimal essential mixtures of cannabinoids based on a step-wise, strategic approach to reducing the complexity of the plant secondary metabolome. The sequential use of insilico, in vitro, and medium throughput in vivo experimental systems has generated refined, de-risked mixtures that can now be tested in additional, higher-cost, preclinical model systems of PD.
Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary GbS Global Biopharma, Inc. The "plant-inspired" active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences' intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences' lead program for Parkinson's disease is being prepared for a first-in-human clinical trial. Gb Sciences' formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada. The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
